Latest News

Mon, November 14, 2011
Kentucky Heart Foundation receives $10,000 grant
The Kentucky Heart Foundation, in partnership with the Healthy Kids, Healthy Communities Coalition and ACHIEVE initiative, recently received a $10,000 grant from the Foundation for a Healthy Kentucky to advocate for complete streets in Boyd and Greenup counties.

Thu, October 13, 2011
Surgical treatment of stroke is topic of professional program
The Kentucky Heart Foundation is pleased to present, The Role of Surgery in the Treatment of Patients with Stroke: The Evidence, a free continuing medical/nursing education program for health professionals. Registration and dinner begin at 5:30 p.m. Thursday, Oct. 20, at the Heritage House Hotel, 1887 U.S. 23.

Thu, September 29, 2011
Health professionals invited to learn about stroke care innovations
King's Daughters Stroke Symposium 2011: Innovations in Stroke Care, will take place Oct. 6 and 7 in the Health Education Center at KDMC. The program has been approved for CME, CNE and continuing education for physical/occupational therapists and radiation operators. Cost for the program is $25, which includes course materials and meals. Full details are available at kdmc.com/register. Registration deadline is 4 p.m. Oct. 3.

We Support a Healthier Future - Healthy People 2020

Recently Added Trials

SCORE Registry

The primary purpose of this registry is to track problems with and long-term performance of St. Jude Medical continuous rhythm devices.

ACUITY (closed - results published)

This trial’s results were published in the New England Journal of Medicine in November 2006. It explored the potential of the injectable anti-clotting medicine Angiomax® (bivalirudin) in patients experiencing ACS. The results showed that Angiomax, in the “Angiomax alone” treatment group, was effective and reduced the risk of major bleeding—a key risk factor for mortality—by 47 percent compared to the standard combination of injectable drugs.

PROVIDE (closed)

The objective of the post-marketing surveillance study id to collect clinical usage patterns of the Benephit Infusion Systems. As a result, AngioDynamics will be able to (1) Better understand and quantify usage patterns including patient characteristics, adjunctive procedures, and infusion agents, (2) Collect user-interface information and overall customer satisfaction, and (3) Monitor post-marketing device performance and safety for quality adherence.

APPRAISE 2 (closed - results published)

The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome.